This Project Grant award of $108,512 from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program supports research at Weill Medical College of Cornell University to investigate the chromatin landscape of alternative lengthening of telomeres (ALT) in cancer cells. The award, effective March 1, 2025 through February 28, 2029, will enable the researcher to: 1) use a base editing screen to identify ATRX domains and functions that suppress ALT, and 2) study the effect of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...
This Project Grant award of $432,614.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, 17p loss, and NDE1 dependence in cancer cells. The goal is to define the genetic dependencies resulting from these factors and assess the therapeutic potential of targeting NDE1 in cancers with increased chromosomal instability and 17p loss. The award period...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
The National Cancer Institute (NCI) awarded a $552,968 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The project aims to use mass spectrometry and ribosome profiling to investigate how altered tRNA modifications influence the translational landscape and drive oncogenic processes in glioblastoma, a highly lethal...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, supports research to decipher the immune evasion mechanisms of cancers harboring mutations in the IDH1 gene. The $196,029 award, effective April 1, 2025 through March 31, 2028, will fund the University of Massachusetts Medical School's investigation into two key processes that contribute to the immunosuppressive tumor microenvironment in IDH1-mutant cancers: 1) the...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
This Project Grant award of $673,526 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Pittsburgh to investigate the mechanistic role of p16 loss in regulating zinc homeostasis through the zinc transporter SLC39A9 and its impact on the efficacy of immune checkpoint blockade therapy in melanoma. The research aims to explore whether manipulating zinc levels can enhance the effectiveness of current immune...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, provides $223,176 to Duke University to investigate the role of SMARCAL1 depletion in promoting increased immunogenicity in alternative lengthening of telomeres (ALT)+ high-grade gliomas (HGGs). The overarching goal is to study how therapeutic targeting of SMARCAL1 can lead to tumor-specific DNA damage and inflammation, potentially overcoming the immunologically "cold" nature of HGGs. The in vitro and in vivo studies will examine the intrinsic and extrinsic inflammatory responses following SMARCAL1 depletion in human ALT+ HGG cell lines and syngeneic murine glioma models. The award period runs from Sep 10, 2025 to Apr 30, 2028.